InvestorsHub Logo
Followers 1
Posts 129
Boards Moderated 0
Alias Born 06/04/2019

Re: l2 hunter post# 75

Monday, 01/18/2021 12:30:34 PM

Monday, January 18, 2021 12:30:34 PM

Post# of 134
The research out of Sloan Kettering on HSP's has huge potential for cancer therapy. I find their developement of analytical methods impressive to say the least. Have you looked at the chaperome inhibition landscape, ADX-1612, and put any sort of value/timing on that part of the business? I'm thinking five years or more to get through trials. 2B market cap? Will covid-19 move that timeline forward? I appreciate any thoughts you may have.

https://www.aldeyra.com/pipeline-disease-areas/systemic-diseases/ovarian-cancer/

Samus Therapeutics is apparently privately held.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ALDX News